Fast Company
2 weeks agoPublic health
Moderna stock plunges nearly 20% as company reports poor COVID-19 vaccine sales and cuts to research plans
Moderna is reducing its R&D budget by 20%, impacting future vaccine development due to low sales projections.
The company faces challenges following its pandemic success, prompting a strategic shift in investment. [ more ]